Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients

Sponsor
Tongji Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05727709
Collaborator
Anapure BioScience (Other), Caibo MedTech (Other), SKM BioTech (Other)
220
4
16.9
55
3.3

Study Details

Study Description

Brief Summary

The goal of this observational study is to learn about dynamic changes of Torquetenovirus (TTV) load in Chinese renal transplant recipients. The main questions it aims to answer are:

  • Is there correlation between TTV load and rejection?

  • Is there correlation between TTV load and infection?

  • Can changes in the TTV load of kidney transplant recipients predict rejection or infection?

Participants will:
  • receive 13 follow-up visits within 1 year after kidney transplantation

  • provide 2 ml of whole blood for TTV load testing and other related testing at each follow-up

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    220 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Dynamic Changes of Torquetenovirus Load in Chinese Renal Transplant Recipients During Immunosuppressive Therapy: A Double-blind Multicenter Prospective Observational Cohort Study
    Anticipated Study Start Date :
    Feb 1, 2023
    Anticipated Primary Completion Date :
    Dec 31, 2023
    Anticipated Study Completion Date :
    Jun 30, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Acute rejection event [From day0 to day365 after kidney transplantation]

      Any biopsy-proven acute rejection and clinical diagnosed acute rejection

    Secondary Outcome Measures

    1. Infection event [From day0 to day365 after kidney transplantation]

      Any bacterial, fungal (including PJP), mycobacterial, or viral (including CMV viremia, EB viremia, BK Viremia, BK Viruria, etc.) infection requiring hospitalization or prolongation of hospitalization, or requiring intravenous antibiotics or therapeutic use of antiviral drugs, or requiring reduction of immunosuppressive drugs

    2. donor-specific antibodies (DSA) [From day0 to day365 after kidney transplantation]

      the development of de novo DSA or a 30% increase of MFI value in preformed DSA

    3. donor derived cell-free DNA [From day0 to day365 after kidney transplantation]

      An increase in absolute or percent donor derived-cell free DNA from 1 month post-transplant

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Receiving ABO compatible renal allotransplantation from the initiation of the study to December 31, 2023

    • Receiving tacrolimus /mycophenolate mofetil(or mycophenolic acid)/prednisone as maintenance immunosuppression after renal transplantation

    • Receiving universal prophylaxis for CMV infection and PJP infection

    Exclusion Criteria:
    • Receiving combined liver-kidney, pancreas-kidney or heart-kidney transplantation

    • Recipients with active hepatitis B or hepatitis C infection

    • Recipients with anticipated irregular follow-up

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The First Affiliated Hospital of Zhejiang University Hangzhou China
    2 Changhai Hospital affiliated to Naval Military Medical University Shanghai China
    3 Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Wuhan China 430030
    4 the First Affiliated Hospital of Xi'an Jiaotong University Xi'an China

    Sponsors and Collaborators

    • Tongji Hospital
    • Anapure BioScience
    • Caibo MedTech
    • SKM BioTech

    Investigators

    • Principal Investigator: Gang Chen, PhD, Tongji Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Gang Chen, Professor, Deputy director of Institute of OrganTransplantation, Tongji Hospital
    ClinicalTrials.gov Identifier:
    NCT05727709
    Other Study ID Numbers:
    • CTTV study
    First Posted:
    Feb 14, 2023
    Last Update Posted:
    Feb 14, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Gang Chen, Professor, Deputy director of Institute of OrganTransplantation, Tongji Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 14, 2023